Back to resultsMK0767 Glipizide Comparator Cardiac Safety Study (0767-018)
Primary Purpose
Diabetes Mellitus, Type 2
Status
Terminated
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
MK0767
Sponsored by
About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion Criteria:
- You are taking at least one medication for high blood sugar
- Age 21 to 80
Exclusion Criteria:
- History of Type 1 Diabetes Mellitus
- Currently on estrogen replacement therapy regimen
- Currently on a weight loss program with ongoing weight loss or taking medications for weight loss
- Having surgery 30 days before starting the study
- Have taken any other investigational drug in the past 90 days
- Have Hepatitis B or C
- Active liver or gallbladder disease
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00543010
Brief Title
MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)
Study Type
Interventional
2. Study Status
Record Verification Date
June 2015
Overall Recruitment Status
Terminated
Study Start Date
November 2002 (undefined)
Primary Completion Date
November 2003 (Actual)
Study Completion Date
November 2003 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck Sharp & Dohme LLC
4. Oversight
5. Study Description
Brief Summary
A study to evaluate the cardiac and metabolic effects of MK0767 in patients with Type 2 Diabetes.
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
247 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
MK0767
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
You are taking at least one medication for high blood sugar
Age 21 to 80
Exclusion Criteria:
History of Type 1 Diabetes Mellitus
Currently on estrogen replacement therapy regimen
Currently on a weight loss program with ongoing weight loss or taking medications for weight loss
Having surgery 30 days before starting the study
Have taken any other investigational drug in the past 90 days
Have Hepatitis B or C
Active liver or gallbladder disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Monitor
Organizational Affiliation
Merck Sharp & Dohme LLC
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)
We'll reach out to this number within 24 hrs